Opportunity
Federal Register #FDA-2026-N-0008
FDA Renews Pharmacy Compounding Advisory Committee for Two Years
Buyer
Food and Drug Administration
Posted
April 30, 2026
Identifier
FDA-2026-N-0008
The Food and Drug Administration (FDA) is announcing the renewal of the Pharmacy Compounding Advisory Committee for an additional two years. - Government Buyer: - Department of Health and Human Services (HHS) - Food and Drug Administration (FDA) - Purpose and Scope: - Renewal of the Pharmacy Compounding Advisory Committee - Committee advises the Commissioner of Food and Drugs on scientific, technical, and medical issues related to drug compounding under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act - Committee includes experts in pharmaceutical compounding, pharmacy, medicine, and related specialties - Representatives from organizations such as the National Association of Boards of Pharmacy and the United States Pharmacopeia participate - No procurement activity: - No products or services are being requested or procured - No vendors or OEMs are mentioned - Notable Requirements: - Renewal aligns with federal regulations for advisory committees - Determined to be in the public interest - Place of Performance/Contracting Office: - Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 1, Rm. 3215, Silver Spring, MD 20993-0002
Description
The Food and Drug Administration (FDA) is announcing the renewal of the Pharmacy Compounding Advisory Committee by the Commissioner of Food and Drugs. The committee is renewed for an additional 2 years beyond the current charter expiration date, extending the charter until April 25, 2028. The committee advises the Commissioner on scientific, technical, and medical issues concerning drug compounding under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Members include experts in pharmaceutical compounding, pharmacy, medicine, and related specialties, as well as representatives from relevant organizations. The renewal aligns with federal regulations for advisory committees and is determined to be in the public interest.